Zacks Research Brokers Boost Earnings Estimates for Omnicell

Omnicell, Inc. (NASDAQ:OMCL) – Equities researchers at Zacks Research boosted their Q2 2025 earnings per share estimates for Omnicell in a research note issued to investors on Tuesday, January 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.23 for the quarter, up from their previous estimate of $0.19. The consensus estimate for Omnicell’s current full-year earnings is $0.94 per share. Zacks Research also issued estimates for Omnicell’s Q2 2026 earnings at $0.32 EPS, Q4 2026 earnings at $0.21 EPS and FY2026 earnings at $1.04 EPS.

Several other brokerages have also issued reports on OMCL. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Bank of America decreased their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Craig Hallum lifted their target price on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Benchmark reissued a “buy” rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. Finally, Barclays lifted their price objective on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $50.00.

Omnicell Stock Performance

NASDAQ OMCL opened at $45.31 on Friday. Omnicell has a one year low of $25.12 and a one year high of $55.74. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of -116.18, a price-to-earnings-growth ratio of 30.57 and a beta of 0.78. The company’s 50-day simple moving average is $44.68 and its two-hundred day simple moving average is $42.64.

Insider Transactions at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.64% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Van ECK Associates Corp boosted its position in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares during the last quarter. KBC Group NV increased its stake in shares of Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after acquiring an additional 778 shares during the period. 1620 Investment Advisors Inc. increased its stake in shares of Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after acquiring an additional 1,542 shares during the period. Finally, Summit Global Investments purchased a new position in shares of Omnicell during the third quarter worth $221,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.